Breast Cancer
Advertisement
Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer.
Hormone therapy was associated with a 19% lower relative risk in Black women aged 65 to 74 years.
A study aimed to assess the long-term survival outcomes and disease patterns of male breast cancer patients.
Researchers developed a tool to predict nervous system side effects experienced by breast cancer patients using taxanes.
A year of treatment with the antibody-drug conjugate trastuzumab emtansine effectively prevents HER2-positive BC ...
Carlos Doti, MD, of AstraZeneca, discusses the impact of LYNPARZA over the last decade.
Dr. Lopetegui-Lia reacts to Dr. Gatti-Mays' breast cancer panel discussion from Advancements in Oncology.
Dr. Margaret Gatti-Mays explains what makes The Oncology Brothers' content so important for community oncologists.
Dr. Margaret Gatti-Mays explains how to address the most pressing questions in triple-negative breast cancer treatments.
Dr. Gatti-Mays discusses how treatment for triple-negative breast cancer has evolved in recent years.
Dr. Margaret Gatti-Mays delves into the topic of HER2 tumor expression in breast cancer.
A study examined the impact of relationship satisfaction and agreement between breast cancer survivors and their partners.
Dr. Gatti-Mays talks about the importance of tailoring treatments to individual patients with breast cancer.
Dr. Margaret Gatti-Mays, who specializes in breast cancer, delivers key insights on many breast cancer-related topics.
Dr. Margaret Gatti-Mays talks with The Oncology Brothers about the right treatments for endocrine-resistant breast cancer.
Dr. Margaret Gatti-Mays details the treatment options for BC patients in the hormone receptor-positive metastatic setting.
Some patients are unaware that metastatic breast cancer is incurable and that their treatment has no established end date.
The Oncology Brothers spoke with Dr. Margaret Gatti-Mays, who provided invaluable insights on hormone receptor-positive BC.
Eribulin is noninferior to trastuzumab and pertuzumab plus taxane in treating HER2-positive breast cancer.
Episodic future thinking may help breast cancer survivors lose weight.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.